Hepatobiliary Malignancies

You have full text access to this OnlineOpen article

Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer†

  1. Gang Hu1,2,‡,*,
  2. Jaakko Tuomilehto1,2,3,
  3. Eero Pukkala4,
  4. Timo Hakulinen4,
  5. Riitta Antikainen5,
  6. Erkki Vartiainen2,
  7. Pekka Jousilahti2

Article first published online: 18 MAR 2008

DOI: 10.1002/hep.22320

Issue

Hepatology

Hepatology

Volume 48, Issue 1, pages 129–136, July 2008

Additional Information

How to Cite

Hu, G., Tuomilehto, J., Pukkala, E., Hakulinen, T., Antikainen, R., Vartiainen, E. and Jousilahti, P. (2008), Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology, 48: 129–136. doi: 10.1002/hep.22320

Author Information

  1. 1

    Department of Public Health, University of Helsinki, Helsinki, Finland

  2. 2

    Department of Health Promotion and Chronic Diseases Prevention, National Public Health Institute, Helsinki, Finland

  3. 3

    South Ostrobothnia Central Hospital, Seinäjoki, Finland

  4. 4

    Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland

  5. 5

    Oulu City Hospital, Oulu, Finland

  1. ‡

    fax: +358 9 19127313.

*Department of Health Promotion and Chronic Diseases Prevention, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 20 JUN 2008
  2. Article first published online: 18 MAR 2008
  3. Accepted manuscript online: 18 MAR 2008 12:00AM EST
  4. Manuscript Accepted: 4 MAR 2008
  5. Manuscript Received: 10 JAN 2008

Funded by

  • Finnish Academy. Grant Numbers: 108297, 119681
  • Special Research Funds of the Social Welfare and Health Board, City of Oulu

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (271K)

References

  • 1
    Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon, France: International Agency for Cancer Research; 2004.
  • 2
    Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. HEPATOLOGY 1995; 22: 1027–1033.
    Direct Link:
  • 3
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–567.
  • 4
    Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112–125.
  • 5
    Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293–300.
  • 6
    Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116: 150–154.
    Direct Link:
  • 7
    Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93: 607–610.
  • 8
    Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007; 132: 1740–1745.
  • 9
    Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. HEPATOLOGY 2007; 46: 430–435.
    Direct Link:
  • 10
    World Resources Institute. Earth Trends Data Tables: Energy and Resources. Available at: http://earthtrends.wri.org/pdf_library/data_tables/ene5_2005.pdf.
  • 11
    Iivonen J, Kela E, Kuusi M, Lyytikäinen O, Ruutu P. Infectious Diseases in Finland 1995-2004. Helsinki, Finland: National Public Health Institute; 2005.
  • 12
    Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293–297.
  • 13
    Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27: 438–443.
  • 14
    Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928–1936.
  • 15
    Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248–1257.
  • 16
    Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klatsky A. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001; 11: 458–465.
  • 17
    Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263–355.
  • 18
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175–1181.
  • 19
    Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000; 29: 49–56.
  • 20
    Pajak A, Kuulasmaa K, Tuomilehto J, Ruokokoski E. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA Project. World Health Stat Q 1988; 41: 115–140.
  • 21
    Tuomilehto J, Hu G, Bidel S, Lindstrom J, Jousilahti P. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA 2004; 291: 1213–1219.
  • 22
    Hu G, Jousilahti P, Nissinen A, Bidel S, Antikainen R, Tuomilehto J. Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am J Clin Nutr 2007; 86: 457–464.
  • 23
    Paalanen L, Mannisto S, Virtanen MJ, Knekt P, Rasanen L, Montonen J, et al. Validity of a food frequency questionnaire varied by age and body mass index. J Clin Epidemiol 2006; 59: 994–1001.
  • 24
    Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365–369.
  • 25
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187–220.
  • 26
    Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62( Suppl 1): 8–17.
  • 27
    Montella M, Polesel J, La Vecchia C, Dal Maso L, Crispo A, Crovatto M, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120: 1555–1559.
    Direct Link:
  • 28
    Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159–S166.
  • 29
    Bidel S, Silventoinen K, Hu G, Lee DH, Kaprio J, Tuomilehto J. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes. Eur J Clin Nutr 2008; 62: 178–185.
  • 30
    La Vecchia C, Negri E, Cavalieri d'Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 1998; 7: 315–320.
  • 31
    Tanaka T, Nishikawa A, Shima H, Sugie S, Shinoda T, Yoshimi N, et al. Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. Basic Life Sci 1990; 52: 429–440.
  • 32
    He P, Noda Y, Sugiyama K. Suppressive effect of coffee on lipopolysaccharide-induced hepatitis in D-galactosamine-sensitized rats. Biosci Biotechnol Biochem 2001; 65: 1924–1927.
  • 33
    Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomilehto J. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89: 5410–5414.
  • 34
    El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369–380.
View Full Article (HTML) Get PDF (271K)